1. Home
  2. Labeler Index
  3. Hospira, Inc.
  4. 0409-4713
  5. NDC Package Code: 0409-4713-02 Lidocaine Hydrochloride

NDC Package 0409-4713-02 Lidocaine Hydrochloride

Injection, Solution Epidural; Infiltration; Intracaudal; Perineural - View Billable Units, 11-Digit Format, RxNorm

Table of Contents

    1. Package Information
    2. Other Packages
    3. Frequently Asked Questions

Package Information

Find all the important details about this NDC Package code, including the 11-Digit NDC Billing number, billing units, wholesale price, RxNorm crosswalk, active ingredients, pharmacologic clasess, etc.

NDC Package Code:
0409-4713-02
Package Description:
5 CELLO PACK in 1 PACKAGE / 5 AMPULE in 1 CELLO PACK (0409-4713-26) / 5 mL in 1 AMPULE (0409-4713-12)
Product Code:
0409-4713
Proprietary Name:
Lidocaine Hydrochloride
Non-Proprietary Name:
Lidocaine Hydrochloride
Substance Name:
Lidocaine Hydrochloride
Usage Information:
Intramuscular Where oral therapy is not feasible, injectable corticosteroid therapy, including triamcinolone acetonide injectable suspension is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis and systemic lupus erythematosus. Intra-Articular The intra-articular or soft tissue administration of triamcinolone acetonide injectable suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. Lidocaine Hydrochloride Injection, USP is indicated for production of local or regional anesthesia by infiltration techniques such as percutaneous injection and intravenous regional anesthesia by peripheral nerve block techniques such as brachial plexus and intercostal and by central neural techniques such as lumbar and caudal epidural blocks, when the accepted procedures for these techniques as described in standard textbooks are observed.
11-Digit NDC Billing Format:
00409471302
Billing Unit:
ML - Billing unit of "milliliter" is used when a product is measured by its liquid volume.
NDC to RxNorm Crosswalk:
  • RxCUI: 1737568 - lidocaine HCl 1 % in 2 ML Injection
  • RxCUI: 1737568 - 2 ML lidocaine hydrochloride 10 MG/ML Injection
  • RxCUI: 1737568 - lidocaine HCl 1 % per 2 ML Injection
  • RxCUI: 1737568 - lidocaine HCl 20 MG per 2 ML Injection
  • RxCUI: 1792144 - triamcinolone acetonide 40 MG in 1 ML Injection
    • Product Type:
    Human Prescription Drug
    Labeler Name:
    Hospira, Inc.
    Dosage Form:
    Injection, Solution - A liquid preparation containing one or more drug substances dissolved in a suitable solvent or mixture of mutually miscible solvents that is suitable for injection.
    Administration Route(s):
  • Epidural - Administration upon or over the dura mater.
  • Infiltration - Administration that results in substances passing into tissue spaces or into cells.
  • Intracaudal - Administration within the cauda equina.
  • Perineural - Administration surrounding a nerve or nerves.
    • Active Ingredient(s):
  • LIDOCAINE HYDROCHLORIDE 10 mg/mL
    • Pharmacologic Class(es):
  • Amide Local Anesthetic - [EPC] (Established Pharmacologic Class)
  • Amides - [CS]
  • Antiarrhythmic - [EPC] (Established Pharmacologic Class)
  • Local Anesthesia - [PE] (Physiologic Effect)
    • Sample Package:
    No
    FDA Application Number:
    ANDA080408
    Marketing Category:
    ANDA - A product marketed under an approved Abbreviated New Drug Application.
    Start Marketing Date:
    07-08-2005
    Listing Expiration Date:
    12-31-2024
    Exclude Flag:
    N
    Code Structure:

    The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

    * Please review the disclaimer below.

    Other Product Packages

    The following packages are also available for this product:

    NDC Package CodePackage Description
    0409-4713-325 CARTON in 1 PACKAGE / 10 AMPULE in 1 CARTON (0409-4713-25) / 2 mL in 1 AMPULE (0409-4713-42)
    0409-4713-62800 AMPULE in 1 CASE / 2 mL in 1 AMPULE (0409-4713-72)
    0409-4713-65800 AMPULE in 1 CASE / 5 mL in 1 AMPULE (0409-4713-75)

    * Please review the disclaimer below.

    Frequently Asked Questions

    What is NDC 0409-4713-02?

    The NDC Packaged Code 0409-4713-02 is assigned to a package of 5 cello pack in 1 package / 5 ampule in 1 cello pack (0409-4713-26) / 5 ml in 1 ampule (0409-4713-12) of Lidocaine Hydrochloride, a human prescription drug labeled by Hospira, Inc.. The product's dosage form is injection, solution and is administered via epidural; infiltration; intracaudal; perineural form.

    Is NDC 0409-4713 included in the NDC Directory?

    Yes, Lidocaine Hydrochloride with product code 0409-4713 is active and included in the NDC Directory. The product was first marketed by Hospira, Inc. on July 08, 2005 and its listing in the NDC Directory is set to expire on December 31, 2024 if the product is not updated or renewed by the manufacturer.

    What is the NDC billing unit for package 0409-4713-02?

    The contents of this package are billed per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.

    What is the 11-digit format for NDC 0409-4713-02?

    The 11-digit format is 00409471302. The 11-digit billing format might be required by the Centers for Medicare & Medicaid Services (CMS) and other payers in billing claim forms.

    This package code is originally configured in a 4-4-2 segment 10-digit format and by adding a zero within the original NDC package code we can obtain the converted 11-digit format in a 5-4-2 segment configuration. The table below shows the 11-digit code conversion:

    10-Digit Format10-Digit Original Code11-Digit Format11-Digit Code
    4-4-20409-4713-025-4-200409-4713-02